61 citations
,
September 2010 in “Journal of Dermatological Science”
This review discusses the interplay between hormonal and immune systems in hairfollicles and reports no new results, highlighting the need for further research on their role in skin biology and alopecia areata.
106 citations
,
January 2013 in “Clinical and Developmental Immunology”
This review discusses the pathogenesis of alopecia areata, highlighting the role of immune privilege collapse in hairfollicles but reports no clinical results.
5 citations
,
November 2008 in “Advances in Dermatology”
This review discusses advancements in understanding hair cycle and inflammatory alopecias, proposing a standard classification and tiered treatment recommendations, but reports no clinical results.
220 citations
,
June 2013 in “The Journal of Pathology”
This study found that immune privilege collapse in the hairfollicle bulge and associated immune responses may contribute significantly to the pathogenesis of lichen planopilaris, suggesting a potential autoimmune basis for the disease.
Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hairfollicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.
PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfollicle stem cells, but minoxidil and finasteride are still the main treatments.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hairfollicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.
The user experienced hair regrowth after using oral minoxidil, topical minoxidil, dutasteride, multivitamins, and ketoconazole shampoo, with noticeable improvement in the hairline after 11 months. They reported a burning sensation on the scalp and questioned if single hairfollicles could become multi-hairfollicles.
What is tofacitinib, and why is it discussed in relation to autoimmune-related hair loss such as alopecia areata?Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.